This page is for healthcare professionals only.
A Galapagos product may be discussed at these events.
Find the abbreviated SmPC here.
This page is not affiliated with UEG.
This symposium was funded and organised by Galapagos.

Galapagos @ UEG Week 2023

 

Galapagos is proud to have been a sponsor of the annual United European Gastroenterology (UEG) Week, one of the biggest events in the gastroenterology calendar!

Each year, the UEG Week scientific programme includes a wide range of sessions presented by some of the world’s leading specialists in IBD, exploring basic science, conventional medicine, clinical practice, as well as a wealth of important new data.

Satellite
symposium

If you missed the live event, you can catch up now and watch Professor Séverine Vermeire, Professor Jonas Halfvarson and Professor Ailsa Hart in the Galapagos-sponsored satellite symposium at UEG Week 2023.

hearFromProfessorVermeire

Watch the recording of our expert faculty to:

  • Learn how and why comprehensive disease control is assessed in clinical practice, and how it can guide treatment decisions for individual patients
  • Hear our experts discuss recent clinical trial data that demonstrate how filgotinib can help deliver comprehensive disease control and share their real-world experiences of using JAK inhibitors in the clinic tailored to patients needs
  • See them in the hot seat as they discuss the practical considerations of initiating treatment with filgotinib

Read how Professor Séverine Vermeire, Professor Jonas Halfvarson and Professor Ailsa Hart addressed the topic of JAK inhibition and individualised care, and what comprehensive management means for patients with UC

Assessing
comprehensive disease
control in UC

In this session, Professors Séverine Vermeire (Chair) and Ailsa Hart explored how understanding patients through the lens of...

Identifying opportunities
for individualised therapy:
the place of JAK inhibition

Professor Jonas Halfvarson walked the audience through the latest clinical trial data on...

JAK to reality:
practicalities of using
filgotinib in the clinic

The whole faculty was involved in this quick-fire, interactive session, which included practical insights on...

Faculty

Abstracts*

Posters and presentations will be made available as soon as they are presented at UEG week (please see individual presentation times below).


Séverine Vermeire, David T Rubin, Mamoru Watanabe, Stefan Schreiber, Rajiv Mehta, Xavier Roblin, Mark C Genovese, Tomasz Masior, Rahul Barron, Franck-Olivier Le Brun and Silvio Danese
Presentation type: oral presentation
Presentation number: OP097
Session: Hit the road JAK: Part 1
Time: 14:30–15:30
Room: D3
Date: 16 October


Brian Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, Margaux Faes, Alessandra Oortwijn, Angela de Haas, Christine Rudolph and Laurent Peyrin-Biroulet
Presentation type: oral presentation
Presentation number: OP148
Session: Hit the road JAK: Part 2
Time: 08:30–09:30
Room: A3
Date: 17 October


Stefan Schreiber, Séverine Vermeire, David T Rubin, Silvio Danese, Rajiv Mehta, Xavier Roblin, Paul Kwon, Paul van Hoek, Tomasz Masior, Rahul Barron, Franck-Olivier Le Brun and Mamoru Watanabe
Presentation type: moderated poster
Presentation number: MP004
Session: Medical therapy of IBD: Facts and Challenges
Time: 10:30–11:30
Room: Science Lounge
Date: 15 October


David Laharie, Andreas Sturm, Taku Kobayashi, Takayuki Matsumoto, Alessandra Oortwijn, Corinne Jamoul, Margaux Faes, Angela de Haas, and Séverine Vermeire
Presentation type: moderated poster
Presentation number: MP003
Session: Medical therapy of IBD: Facts and Challenges
Time: 10:30–11:30
Room: Poster Stage 1
Date: 15 October


Taku Kobayashi, Axel Dignass, Xavier Roblin, Yasushi Fujitani, Alessandra Oortwijn, Corinne Jamoul and Toshifumi Hibi
Presentation type: moderated poster
Presentation number: MP324
Session: IBD: We treat them all but how?
Time: 16:00–17:00
Room: Poster stage 1
Date: 16 October


*Filgotinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib is not approved for Crohn's disease. 
Filgotinib should only be used if no suitable treatment alternatives are available in patients 65 years of age and older, with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), or with malignancy risk factors (e.g. current malignancy or history of malignancy).

Posters and presentations will be made available as soon as they are presented at UEG week (please see individual presentation times below).


Brian Feagan, Séverine Vermeire, Silvio Danese, Laurent Peyrin-Biroulet, Bart Eskens, Margaux Faes, Alessandra Oortwijn and Stefan Schreiber
Presentation type: ePoster
Poster presentation number: PP0834
Poster topic: PP 05 IBD
Session: ePoster Session
Room: Science Lounge
Date: 14–17 October


*Filgotinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib is not approved for Crohn's disease. 
Filgotinib should only be used if no suitable treatment alternatives are available in patients 65 years of age and older, with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), or with malignancy risk factors (e.g. current malignancy or history of malignancy).

News and views

Stay up to date!

I would like to receive informational and promotional communication via e-mail concerning Galapagos' products and services. 

This field is required
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
The number is too long
Value did not matched with each other.
This field is required
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.

Related events


See all our events

Visit our website to register for access to our full catalogue of medical education!